Brief: Erasca Granted FDA Fast Track Designation For CNS-Penetrant EGFR Inhibitor ERAS-801 In Patients With Glioblastoma

Erasca

01/05/2023 13:15

May 1 (Reuters) - Erasca Inc  ERAS.O :
    * ERASCA GRANTED FDA FAST TRACK DESIGNATION FOR
CNS-PENETRANT EGFR
INHIBITOR ERAS-801 IN PATIENTS WITH GLIOBLASTOMA
    * ERASCA INC - INITIAL THUNDERBBOLT-1 PHASE 1 DATA IN
PATIENTS
WITH RECURRENT GBM EXPECTED IN H2 2023

Source text for Eikon:  ID:nGNX7lcqbV 
Further company coverage:  ERAS.O 

 ((Reuters.Briefs@thomsonreuters.com;))